PROKIDNEY CORP. 10-K

Item 5 . Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Market Information Our Class A ordinary shares are listed on the Nasdaq Capital Market under the symbol “PROK”. Dividend Policy No cash dividends have ever been declared or paid on the common equity to date by the Company. Holders As of March 21, 2024, we had approximately 61,621,330 Class A ordinary shares issued and outstanding held by 39 holders of record and approximately 167,722,201 Class B ordinary shares issued and outstanding held by three holders of record. Because a large portion of our Class A ordinary shares are held by brokers, nominees and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders. There is no public market for our Class B ordinary shares. Unregistered Sales of Securities Not applicable. Issuer Purchases of Equity Securities The following table reports information regarding repurchases of the Company’s Class A ordinary shares during the quarter ended December 31, 2023: 93 Period Total Number of Shares Purchased (1) Average Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs October 1 - 31, 2023 – $ – – – November 1 - 30, 2023 7,256,367 $ 1.309 – – December 1 - 31, 2023 – $ – – – Total 7,256,367 – – (1) On November 19, 2023, ProKidney Corp. (the “Company”) entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with SC PIPE Holdings LLC and SC Master Holdings, LLC (the “Selling Shareholders”), pursuant to which the Company agreed to repurchase an aggregate of its 7,256,367 Class A ordinary shares, par value $0.0001 per share from the Selling Shareholders for a purchase price per share of $1.309 (the “Share Repurchase”). The aggregate price paid by the Company in the Share Repurchase is approximately $9.5 million. The Share Repurchase closed on November 21, 2023. The Share Repurchase was unanimously approved by ProKidney’s Board of Directors and was not made as part of any existing share repurchase program. Item 6 . RESERVED.